CCM
SGMO

Chiron Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Chiron Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-500
Closed -$5K – 376
2020
Q3 		$5K Buy
+500
New +$5.41K ﹤0.01% 372

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Chiron Capital Management's SGMO Position: Q4 2020 in Review

Chiron Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2020, closing a stake of 500 shares — an estimated $5K sold.

Chiron Capital Management first reported a position in SGMO in Q3 2020 and held it in 1 quarter. The position peaked at $5K in Q3 2020. 223 funds tracked by Wall St. Rank hold SGMO as of Q4 2020.

  • Chiron Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2020 after selling out during the quarter.
  • Chiron Capital Management sold 500 SANGAMO THERAPEUTICS INC shares in Q4 2020, an estimated $5K.
  • Chiron Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q3 2020 and held it in 1 quarter.
  • Chiron Capital Management's SANGAMO THERAPEUTICS INC position peaked at $5K in Q3 2020.
  • 223 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2020.

Based on Chiron Capital Management's 13F filing for Q4 2020, filed 5 Mar 2021.